Novo Nordisk's (NVO) Wegovy receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. CRWV
8. CME
9. ADBE
10. HUMA

Go back to Novo Nordisk's (NVO) Wegovy receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity

Novo Nordisk (NOVOB:DC) (NVO) PT Raised to DKK1,054 at TD Cowen

March 11, 2024 2:03 PM EDT

TD Cowen analyst Steve Scala raised the price target on Novo Nordisk (NOVOB:DC) (NYSE: NVO) to DKK1,054.00 (from DKK925.00) while maintaining a Outperform rating.

The analyst comments "Novo announced FDA approval of the expanded label for Wegovy, now indicated to reduce CV risk in people with both obesity and CVD based on data from SELECT. Though these data are widely appreciated by specialists after... More